Trials / Completed
CompletedNCT01456715
Immunogenicity of Gardasil and Twinrix and the Effect of a Dose of Gardasil or Cervarix Given 42 Months Later.
Immunogenicity and Safety of Gardasil and Twinrix Vaccines Co-administered or Administered a Month Apart, According to the 0, 6 Months Schedule and the Effect of a Third Dose of Gardasil or Cervarix Administered 42 Months Later.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 418 (actual)
- Sponsor
- Laval University · Academic / Other
- Sex
- Female
- Age
- 12 Years – 14 Years
- Healthy volunteers
- Accepted
Summary
Two human papillomavirus vaccines are now commercially available. No clinical data exist regarding: * The immunogenicity and safety of Gardasil and Twinrix when co-administered. * The immunogenicity and safety of Cervarix when administered to subjects previously vaccinated with Gardasil. The main objective of the first phase of this clinical trial was: • To assess and compare the immunogenicity of Gardasil and Twinrix Junior when co-administered or administered at one month interval according to a 0, 6 month schedule to 9-10 year-old girls. The main objective of the seconde phase of this clinical trial is: • To determine the effect of a booster dose of Gardasil or Cervarix on HPV antibodies when given 42 months post-vaccination of 9-10 year-old girls with two doses of Gardasil. Study Design \& Duration: Experimental Design: Blind for the third HPV vaccine dose, randomized, single centre study with two treatment groups. Duration of the study: Participants will be followed for the duration of 10 years post-primary vaccination. Number of Centres: One Center.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Gardasil vaccine, Immunogenicity, Booster dose. | Gardasil vaccine given according to the 0,6 months schedule and a booster dose of Gardasil given 42 months later. |
| BIOLOGICAL | Cervarix Vaccine, Immunogenicity, Booster Dose. | Gardasil vaccine given according to the 0,6 months schedule and a booster dose of Cervarix given 42 months later. |
Timeline
- Start date
- 2008-09-01
- Primary completion
- 2018-12-01
- Completion
- 2018-12-01
- First posted
- 2011-10-21
- Last updated
- 2020-03-05
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT01456715. Inclusion in this directory is not an endorsement.